Has Jo Anne Young, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,825 in general payments to Jo Anne Young, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jo Anne Young, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jo Anne Young, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jo Anne Young, MD

Infectious Disease · Minneapolis, MNNPI 1326149519

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,475 of the $1,825 with a category attached, or 80.8%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 80.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $1,491 and has fallen 93.1% since, to $103 in 2025.

$1,825in general payments, 2019–2025

Across 5 payments — averaging $364.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$1K
National Marrow Donor Program$317
Insmed, Inc.$32

$711,057in research payments, 2019–2025

Across 106 payments — averaging $6708.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Astellas Pharma Global Development$191K
Takeda Pharmaceuticals U.S.A., Inc.$151K
Nobelpharma America, LLC$145K
Shire North American Group Inc$94K
Scynexis, Inc.$59K
Janssen Research & Development, LLC$30K
plus $40K from 4 others

What the payments were for

Consulting fees$1,47581%
Food & beverage$31717%
Education$322%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	1	$1,475
National Marrow Donor Program	2	$317
Insmed, Inc.	2	$32

How this compares

$1,825 in reported general payments places this provider in the 85th percentile of 157 infectious disease providers in Minnesota.

See all infectious disease providers in Minnesota →

Medicare billing

Part B allowed, 2024

$19,693

Medicare patients

Services billed

173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Minneapolis

Frank RhameMinneapolis$132K
William HenryMinneapolis$7K
William StaufferMinneapolis$5K
Grishma TrivediMinneapolis$3K
Alison BormannMinneapolis$3K
Karam ObeidMinneapolis$3K
David BoulwareMinneapolis$2K
Michele GranadaMinneapolis$430
Christian SchrockMinneapolis$230
Daniel ShapiroMinneapolis$178

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →